Pacific Biosciences of California 

$1.3600
388
-$0.04-2.86% Friday 20:00
-$0.01-0.74%Friday 22:40After hours

Statistics

Day High
1.43
Day Low
1.32
52W High
2.73
52W Low
1.09
Volume
7,809,158
Avg. Volume
6,189,024
Mkt Cap
422.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-1.44
-0.96
-0.47
0.01
Expected EPS
-0.14
Actual EPS
N/A

Financials

-341.47%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
160.01MRevenue
-546.38MNet Income

Analyst Ratings

1.50Average Price Target
The highest estimate is 1.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
0%
Sell
100%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PACB. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap28.78B
Illumina offers sequencing and array-based solutions for genetic and genomic analysis, directly competing in the DNA sequencing market with PACB.
Bionano Genomics
BNGO
Mkt Cap13.77M
Bionano Genomics provides optical genome mapping solutions, which compete with PACB's long-read sequencing technologies.
Thermo Fisher Scientific
TMO
Mkt Cap195.86B
Thermo Fisher Scientific offers a range of sequencing and genetic analysis products, competing in the broader genomics space with PACB.
Qiagen NV
QGEN
Mkt Cap8.56B
Qiagen offers sample to insight solutions including sequencing technologies that compete with PACB's offerings.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is involved in CRISPR gene editing, a field that relies on accurate DNA sequencing, where PACB's technologies are used.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine operates in the genome editing space, competing indirectly by relying on sequencing technologies similar to those offered by PACB for its gene editing projects.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is engaged in gene-based medicine, depending on sequencing technologies where PACB's long-read capabilities are beneficial.
Agenus
AGEN
Mkt Cap139.5M
Agenus is involved in immuno-oncology, a field that increasingly relies on genomic sequencing for personalized medicine, indirectly competing with PACB.
Guardant Health
GH
Mkt Cap21.22B
Guardant Health focuses on liquid biopsies and cancer diagnostics, using sequencing technologies that compete with PACB's offerings in the genomic analysis market.

About

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Show more...
CEO
Mr. Christian O. Henry M.B.A.
Employees
575
Country
United States
ISIN
US69404D1081

Listings

0 Comments

Share your thoughts

FAQ

What is Pacific Biosciences of California stock price today?
The current price of PACB is $1.36 USD — it has decreased by -2.86% in the past 24 hours. Watch Pacific Biosciences of California stock price performance more closely on the chart.
What is Pacific Biosciences of California stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pacific Biosciences of California stocks are traded under the ticker PACB.
Is Pacific Biosciences of California stock price growing?
PACB stock has fallen by -5.56% compared to the previous week, the month change is a -17.58% fall, over the last year Pacific Biosciences of California has showed a -11.69% decrease.
What is Pacific Biosciences of California market cap?
Today Pacific Biosciences of California has the market capitalization of 422.42M
When is the next Pacific Biosciences of California earnings date?
Pacific Biosciences of California is going to release the next earnings report on August 05, 2026.
What were Pacific Biosciences of California earnings last quarter?
PACB earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.14 USD resulting in a +78.82% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pacific Biosciences of California revenue for the last year?
Pacific Biosciences of California revenue for the last year amounts to 160.01M USD.
What is Pacific Biosciences of California net income for the last year?
PACB net income for the last year is -546.38M USD.
How many employees does Pacific Biosciences of California have?
As of July 26, 2026, the company has 575 employees.
In which sector is Pacific Biosciences of California located?
Pacific Biosciences of California operates in the Health & Wellness sector.
When did Pacific Biosciences of California complete a stock split?
Pacific Biosciences of California has not had any recent stock splits.
Where is Pacific Biosciences of California headquartered?
Pacific Biosciences of California is headquartered in Menlo Park, United States.